Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 4
1990 1
1991 2
1992 3
1993 3
1994 4
1995 3
1996 3
1997 4
1998 5
1999 6
2000 8
2001 7
2002 10
2003 12
2004 6
2005 17
2006 13
2007 7
2008 1
2009 3
2010 6
2011 4
2012 6
2013 4
2014 2
2015 3
2016 5
2017 4
2018 8
2019 4
2020 4
2021 5
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

162 results
Results by year
Filters applied: . Clear all
Page 1
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.
Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu R, Burggraaff CN, Nijland M, Tonino SH, Arens AIJ, Valkema R, van Tinteren H, Lopez-Yurda M, Diepstra A, De Jong D, Hagenbeek A. Kersten MJ, et al. Among authors: valkema r. Haematologica. 2021 Apr 1;106(4):1129-1137. doi: 10.3324/haematol.2019.243238. Haematologica. 2021. PMID: 32273476 Free PMC article. Clinical Trial.
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, Biermann K, van der Gaast A, van Hillegersberg R, Hulshof MCCM, Krishnadath KK, Lagarde SM, Nieuwenhuijzen GAP, Oostenbrug LE, Siersema PD, Schoon EJ, Sosef MN, Steyerberg EW, van Lanschot JJB; SANO study group. Noordman BJ, et al. Among authors: valkema r. Lancet Oncol. 2018 Jul;19(7):965-974. doi: 10.1016/S1470-2045(18)30201-8. Epub 2018 Jun 1. Lancet Oncol. 2018. PMID: 29861116
Neoadjuvant chemoradiotherapy for resectable oesophageal cancer.
Eyck BM, van der Wilk BJ, Lagarde SM, Wijnhoven BPL, Valkema R, Spaander MCW, Nuyttens JJME, van der Gaast A, van Lanschot JJB. Eyck BM, et al. Among authors: valkema r. Best Pract Res Clin Gastroenterol. 2018 Oct-Dec;36-37:37-44. doi: 10.1016/j.bpg.2018.11.007. Epub 2018 Nov 22. Best Pract Res Clin Gastroenterol. 2018. PMID: 30551855 Review.
Peptide receptor radionuclide therapy.
Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Krenning EP, et al. Among authors: valkema r. Ann N Y Acad Sci. 2004 Apr;1014:234-45. doi: 10.1196/annals.1294.026. Ann N Y Acad Sci. 2004. PMID: 15153440 Review.
Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer.
van der Wilk BJ, Eyck BM, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. van der Wilk BJ, et al. Among authors: valkema r. Dig Surg. 2019;36(6):462-469. doi: 10.1159/000493435. Epub 2018 Sep 18. Dig Surg. 2019. PMID: 30227434 Free PMC article. Review.
Bisphosphonates in osteoporosis?
Bijvoet OL, Valkema R, Löwik CW, Papapoulos SE. Bijvoet OL, et al. Among authors: valkema r. Osteoporos Int. 1993;3 Suppl 1:230-6. doi: 10.1007/BF01621915. Osteoporos Int. 1993. PMID: 8461570 Review. No abstract available.
Neuroendocrine tumors. Peptide receptor radionuclide therapy.
Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Forrer F, et al. Among authors: valkema r. Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):111-29. doi: 10.1016/j.beem.2007.01.007. Best Pract Res Clin Endocrinol Metab. 2007. PMID: 17382268 Review.
Peptide-receptor radionuclide therapy for endocrine tumors.
van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ. van Essen M, et al. Among authors: valkema r. Nat Rev Endocrinol. 2009 Jul;5(7):382-93. doi: 10.1038/nrendo.2009.105. Epub 2009 Jun 2. Nat Rev Endocrinol. 2009. PMID: 19488074 Review.
162 results